ArticleCancer science2025
CTCF Is Essential for the Development and Maintenance of CALM-AF10-Induced Leukemia.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
CALM (Clathrin Assembly Lymphoid Myeloid Leukemia)-AF10, a fusion gene commonly associated with acute myeloid leukemia (AML), arises from the t(10;11) translocation and is linked to poor prognosis. In this study, we demonstrate that the CCCTC-binding factor (CTCF) plays a critical role in both the initiation and maintenance of CALM-AF10-induced AML (CALM-AF10 AML). In vivo, CTCF deficiency significantly extended the survival of CALM-AF10 AML mice. In vitro, CTCF knockout (KO) reduced the colony-forming capacity of CALM-AF10 AML cells and induced their differentiation into macrophage-like cells. RNA sequencing (RNA-seq) of CTCF KO cells revealed that Transglutaminase 2 (TGM2) was the most significantly downregulated gene. Chromatin immunoprecipitation sequencing (ChIP-seq) analysis indicated increased repressive histone mark, H3K27 trimethylation (H3K27me3), accompanied by reduced active histone marks, including H3K4 trimethylation (H3K4me3) and H3K27 acetylation (H3K27ac), at the transcription start site (TSS) of Tgm2 following CTCF KO. Knockdown of Tgm2 using short hairpin RNA (shRNA) in CALM-AF10 AML cells and in the human leukemic cell line U937 harboring the CALM-AF10 fusion gene resulted in reduced colony formation and proliferation. This also promoted differentiation into macrophage-like cells, recapitulating the effects observed with CTCF KO. Similarly, comparable outcomes were observed with GK921, a TGM2 inhibitor, highlighting the impact of TGM2 blockade. These findings suggest that CTCF regulates TGM2 expression by modulating post translational modifications of histones at its TSS, thereby preserving the undifferentiated state of CALM-AF10 AML cells. The demonstrated efficacy of TGM2 inhibitors further underscores the importance of TGM2 in this subtype of leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.